The new version of the National Medical Insurance Drug Catalog will officially take effect on January 1, 2026. It is understood that Innovent Biologics' innovative drug for the treatment of thyroid eye disease...The first prescription for Tetumumab N01 injection (Symbim) after it was included in medical insurance was issued nationwide by the team of Academician Fan Xianqun from the Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine.

This drug is the first domestically produced targeted therapy for thyroid eye disease in 70 years. Thyroid eye disease is a common orbital disease affecting over 4 million people in China, often leading to protruding eyeballs and vision impairment. Previously, effective treatments were limited. Tetumumab is China's first and only targeted therapy covered by medical insurance that can reverse protruding eyeballs, achieving a response rate of 85.8% and an overall ocular efficacy of 94.2%. With inclusion in medical insurance, the drug's price has decreased by approximately 60%, significantly reducing the financial burden on patients. Since its approval for thyroid eye disease in early 2025, this drug has been widely used in China.

Industry insiders point out that, according to the unified deployment of the National Healthcare Security Administration, the 2025 edition of the National Medical Insurance Drug Catalog will be officially implemented nationwide on January 1, 2026. This means that from that day forward, newly included drugs are technically eligible for medical insurance reimbursement. However, for patients to actually use these drugs in hospitals, several key steps are still required, including completing the listing on provincial drug procurement platforms and having the newly added drugs included in the hospital's drug catalog through a pharmacy committee meeting.

In an interview with the media, Li Yanshou, Vice President of Innovent Biologics Group, pointed out that by 2025, the drug had already achieved market access in nearly 100 hospitals in China through various means, including formal access, routine procurement, and direct connection with HIS (Hospital Information System). Given that Cibimin is already included in the national medical insurance catalog, the company will next focus on participating in the pharmacy committee meetings for nationally negotiated drugs held at various hospitals to select drugs for hospital admission.

On January 1st, Dr. Sun Jing, Chief Physician of Ophthalmology at the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, issued the first prescription nationwide for tetumumab N01 since it was included in medical insurance coverage for Mr. Yu, a 38-year-old patient. Last May, Mr. Yu sought medical attention at a local hospital due to bilateral eyelid swelling, protruding eyeballs, and double vision. He was diagnosed with thyroid eye disease. Traditional hormone therapy provided temporary relief for the redness and swelling, but the effect only lasted 2-3 days, and the protruding eyeballs continued to worsen. Subsequently, Mr. Yu consulted the Ophthalmology Department of Shanghai Ninth People's Hospital, where he was diagnosed with moderate to severe active thyroid eye disease (TED) and began treatment with the targeted drug tetumumab N01. His protruding eyeballs subsided, the eye inflammation significantly reduced, and his double vision also improved.

In the 2025 national medical insurance negotiations, seven innovative products from Innovent Biologics were successfully included in the new version of the "National Basic Medical Insurance" .The National Reimbursement Drug List (2025) includes drugs covered by maternity and work-related injury insurance. It is understood that Innovent Biologics has launched 17 innovative drugs , 12 of which are included in the National Reimbursement Drug List.

https://finance.eastmoney.com/a/202601043607804443.html